Corticosteroids to Treat Pancreatitis

Description

This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.

Conditions

Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone

Talk to us

Study Overview

On this page

Study Details

Study overview

This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.

Corticosteroids to Reduce Inflammation in Severe Pancreatitis: A Randomized, Controlled Study

Corticosteroids to Treat Pancreatitis

Condition
Pancreatitis
Intervention / Treatment

-

Contacts and Locations

Boston

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, 02215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adult (≥18 years)
  • 2. Acute pancreatitis as defined by a clinical diagnosis of pancreatitis and a lipase level ≥3x the upper limit of normal.
  • 3. Admission or planned admission to an intensive care unit
  • 4. SOFA disease severity score ≥3 (or at least 3 points above a known baseline)
  • 1. Known diagnosis of autoimmune pancreatitis
  • 2. Existing clinical indication for corticosteroids at a dose \>5mg of oral prednisone daily (or equivalent)
  • 3. Contraindication to receiving corticosteroids
  • 4. Protected populations (prisoners)
  • 5. Pregnancy

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Beth Israel Deaconess Medical Center,

Michael Donnino, MD, PRINCIPAL_INVESTIGATOR, Beth Israel Deaconess Medical Center

Study Record Dates

2027-04